New Drug Mavacamten Shows Groundbreaking Results for Heart Disease Patients

A new drug called mavacamten has shown strong results in treating obstructive hypertrophic cardiomyopathy (oHCM). The findings, published in Circulation: Genomic and Precision Medicine, reveal significant improvements in patients' heart function and symptoms. Bristol Myers Squibb now markets the treatment under the brand name Camzyos.

The study tracked patients receiving mavacamten as a standalone therapy. By the end of treatment, most participants no longer met the clinical threshold for obstruction. Their left ventricular outflow tract gradient—a key measure of heart strain—dropped by 35 to 59 mmHg on average.

Symptom relief was also notable. Around 60% of patients improved by at least one NYHA functional class, a standard scale for heart failure severity. These outcomes highlight the drug's potential to transform oHCM management.

Bristol Myers Squibb's $13.1 billion acquisition of MyoKardia in 2020 underscored mavacamten's promise. The company is now expanding its use, testing the drug in adolescents and long-term adult studies. This push aims to strengthen its foothold in the global market for specialised cardiac therapies.

The results confirm mavacamten's effectiveness in reducing obstruction and easing symptoms for oHCM patients. With ongoing trials and broader applications in development, the drug could soon benefit more people with this condition. Bristol Myers Squibb continues to invest in its expansion as a leading cardiac treatment.